Trial Tuesday: Still Feeling The Ripples Of The Lp(a)HORIZON Failure
The detailed pelacarsen readout and its read-through to Amgen and Lilly, plus Regeneron, GSK and Merck making their MASH case.
One edition, every weekday. The story behind the headlines, and how to act on them before your next call.
Published by Norstella's News & Insights division, the team behind Pink Sheet, Scrip, In Vivo and the rest of the industry's most-read mastheads.
The detailed pelacarsen readout and its read-through to Amgen and Lilly, plus Regeneron, GSK and Merck making their MASH case.
Windward Bio raised $225m in a traditional IPO, while Mentari’s reverse merger brought in $490m and Brains Bioceutical chose a SPAC, showing biotechs are finding many ways to reach public money.
The global market for acquiring pharmaceutical innovation has changed faster than our understanding of its consequences for financing discovery.
Oyster Therapeutics has a new name and $60m to take a self-assembling brain degrader toward the clinic. Boehringer Ingelheim plans to file survodutide in obesity in 2027, but MASH could be its best shot at standing out.
Democratic control of Congress means worries about pricing legislation and oversight hearings, but a stouter defense of regular order at FDA – assuming the drug industry can help get the user fee renewal legislation over the finish line.
The UK has sped up how fast a study starts. The ABPI says the unsolved part is getting every site open and recruiting.
Servier paid about 58% of the maximum price before the pivotal data arrived. This week’s deals show what upfront money secures and what it doesn’t.
The count is far from 2021’s 107, but this year’s $306.6m average is the highest of the past seven years. Bambusa and Aspen, the latest two, came in under it.